SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Neuraltus Pharmaceuticals, Inc. Announces Phase 2 Clinical Results for NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS)